AstraZeneca submits Axanum MAA

AstraZeneca plc (LSE:AZN; NYSE:AZN) submitted an MAA in Europe for Axanum aspirin/esomeprazole to prevent cardiovascular and cerebrovascular events in patients requiring continuous low-dose aspirin treatment who are at risk of developing aspirin-associated gastric and/or duodenal ulcers. The MAA was submitted under the EU's decentralized procedure, with Germany acting as the reference member state. ...